RecruitingNCT05452772
Psilocybin or niacin for tobacco cessation
About this title
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Read the official source — NCT05452772Medication studyAges 21+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 21 years.
- Listed locations
- Birmingham and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 66
- Sponsor
- Johns Hopkins University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 21 Years
- Official registry ID
- NCT05452772
- Official title
Show the full official title
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Recruitment & locations
RecruitingBirmingham · Baltimore · New York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Johns Hopkins University, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin and Niacin.
Who can participate?
Listed age limits: from 21 years.
Is this study still recruiting?
The registry lists this study as recruiting.
